pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 30·1 min read
save

Rep. Tom Kean Jr. Discloses Depression Diagnosis After Four-Month Congressional Absence

Jun 30, 2026·read at STAT ↗Neutral

Rep. Tom Kean Jr., a Republican congressman from New Jersey, announced on the House floor that he has been receiving treatment for depression, which explains his unexplained four-month absence from Congress.

He described the illness as both physical and emotional and said that only personal experience can reveal how powerful it is. He added that he kept the condition private because he is a private person by nature.

Kean returned after winning an uncontested primary on June 2 and after his last vote on March 5. His prolonged absence had created difficulties for House Republican leaders trying to pass bills with their narrow majority.

Following his brief remarks, he left the Capitol quickly and declined to answer reporters, offering no further details about his hospitalization or treatment plan.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Republican Tom Kean Jr. reveals depression diagnosis after his four-month absence from Congress”

read at STAT ↗
925 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ELI LILLY COEli Lilly and CoLILLYNOVONovo Nordisk Inc
drugs
Obesity
topics
Major Depression12Gene Therapy (AAV)ObesityPsychiatry & CNS

related stories

  • Jun 30STAT+: Even with MAHA, Trump administration has gone soft on alcoholSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Aug 19Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, moreBioSpace
  • Aug 5Lilly confident in slow and steady Foundayo launch, as ex-US sales shineBioSpace
  • Jul 20Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independenceBioSpace